Abstract
Objective
Design
Participants
Methods
Main Outcome Measure
Results
Conclusions
Résumé
Objectif
Nature
Participants
Méthodes
Principal paramètre de mesure
Résultats
Conclusions
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyReferences
- Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye.Can J Ophthalmol. 2009; 44 Suppl 1: S7-93
National Institute for Health and Care Excellence (NICE). Glaucoma: diagnosis and management guidelines 2017. https://www.nice.org.uk/guidance/ng81(accessed September 8, 2018).
- Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines.American Academy of Ophthalmology, San Francisco, CA2015
- Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis.Ophthalmology. 2016; 123: 129-140
- A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension.Eur J Ophthalmol. 2008; 18: 408-416
- Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.Surv Ophthalmol. 2001; 45 Suppl 4: S353-S360
- Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.Clin Ophthalmol. 2015; 9: 633-643
- Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan.Can J Ophthalmol. 2006; 41: 449-456
- Medical management of glaucoma in the 21st century from a Canadian perspective.J Ophthalmol. 2016; 20166509809
- Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.Surv Ophthalmol. 2008; 53: S107-S120
- Prostaglandin FP agonists alter metalloproteinase gene expression in sclera.Invest Opthalmol Vis Sci. 2004; 45: 4368
- A review of the use of latanoprost for glaucoma since its launch.Expert Opin Pharmacother. 2012; 13: 723-745
- Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.Drugs Aging. 2009; 26: 1049-1071
- Latanoprost as a new horizon in the medical management of glaucoma.Curr Opin Ophthalmol. 1996; 7: 11-17
- The effect of latanoprost on intraocular pressure during 2 years of treatment.Surv Ophthalmol. 2002; 47 Suppl 1: S65-S76
- Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.Ophthalmology. 1995; 102: 1743-1752
- Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.Jpn J Ophthalmol. 1993; 37: 270-274
- Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens.Ophthalmology. 1993; 100: 1305-1311
- Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.Surv Ophthalmol. 1997; 41 Suppl 2: S77-S81
- Effectiveness of intraocular pressure-lowering medication determined by washout.JAMA Ophthalmol. 2014; 132: 390-395
- Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.Clin Ther. 2004; 26: 84-91
- Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.Am J Ophthalmol. 2006; 141: 1131-1133
- The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure.J Ocul Pharmacol Ther. 2004; 20: 321-327
- Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.Br J Ophthalmol. 1997; 81: 370-372
- Washout periods for brimonidine 0.2% and latanoprost 0.005%.Am J Ophthalmol. 2001; 131: 798-799
- Washout duration of prostaglandin analogues: a systematic review and meta-analysis.J Ophthalmol. 2018; 20183190684
- A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.Am J Ophthalmol. 2003; 135: 688-703
- GLIMMPSE: online power computation for linear models with and without a baseline covariate.J Stat Softw. 2013; 54: i10
- A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.Am J Ophthalmol. 2001; 131: 636-642
- Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension.Ophthalmology. 2001; 108: 1439-1444
- The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo.Vis Res. 2011; 51: 235-242
- Effects of prostaglandin analogues on aqueous humor outflow pathways.J Ocul Pharmacol Ther. 2014; 30: 102-109
- Effects of prostaglandins on the aqueous humor outflow pathways.Surv Ophthalmol. 2002; 47 Supplement 1: S53-S64
- Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide.Invest Ophthalmol Vis Sci. 2003; 44: 4419-4426
- Effects of long-term topical prostaglandin therapy on central corneal thickness.J Ocul Pharmacol Ther. 2014; 30: 440-444
- Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues.Indian J Ophthalmol. 2015; 63: 15-19
- Effect of corneal thickness on intraocular pressure measurements with the pneumotonometer, Goldmann applanation tonometer, and Tono-Pen.Invest Ophthalmol Vis Sci. 2002; 43: 1389-1392
Article info
Publication history
Footnotes
Presented at the Canadian Ophthalmology Society Annual Meeting, Ottawa, Ontario, Canada, June 18, 2016, American Glaucoma Society annual Meeting, Fort Lauderdale, Florida, USA, March 3, 2016.